ImmuCell
ICCC
13 hedge funds and large institutions have $939K invested in ImmuCell in 2013 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
30% more funds holding
Funds holding: 10 → 13 (+3)
30% more capital invested
Capital invested by funds: $725K → $939K (+$214K)
2.21% more ownership
Funds ownership: 5.09% → 7.31% (+2.2%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$6.06K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.39K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$14.1K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$7.04K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$3.58K |
ICCC Hedge Fund Activity: Q4 2013 in Review
13 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q4 2013, worth a combined $939K — up 30% from $725K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ICCC positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $6.06K. The largest seller was Morgan Stanley, cutting an estimated $14.1K.
- 13 institutional investors held ImmuCell (ICCC) as of Q4 2013, up from 10 in Q3 2013.
- Funds reported $939K of ImmuCell stock for Q4 2013, up 30% quarter-over-quarter.
- 3 funds opened new ImmuCell positions in Q4 2013 and 0 closed out, a net change of +3 holders.
- The largest ImmuCell buyer in Q4 2013 was Renaissance Technologies, an estimated $6.06K added.
- The largest ImmuCell seller in Q4 2013 was Morgan Stanley, an estimated $14.1K sold.
Based on aggregated 13F filings for Q4 2013.